-
Product Insights
NewNet Present Value Model: Mirum Pharmaceuticals Inc’s Volixibat potassium
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
Innovation and Patenting activity of Mirum Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Mirum Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewNet Present Value Model: Marker Therapeutics Inc’s Zelenoleucel
Empower your strategies with our Net Present Value Model: Marker Therapeutics Inc's Zelenoleucel report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Volixibat Potassium in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Volixibat Potassium in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Volixibat Potassium in Primary Biliary Cholangitis (Primary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Biliary Atresia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maralixibat Chloride in Biliary Atresia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maralixibat Chloride in Biliary Atresia Drug Details: Maralixibat chloride (Livmarli)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maralixibat Chloride in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maralixibat Chloride in Primary Sclerosing Cholangitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maralixibat Chloride in Primary Sclerosing Cholangitis Drug Details: Maralixibat...
-
Product Insights
Cholestasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cholestasis - Drugs In Development, 2023’, provides an overview of the Cholestasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cholestasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Progressive Familial Intrahepatic Cholestasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Progressive Familial Intrahepatic Cholestasis - Drugs In Development, 2023’, provides an overview of the Progressive Familial Intrahepatic Cholestasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Familial Intrahepatic Cholestasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Primary Sclerosing Cholangitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Drugs In Development, 2023’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...